The present invention provides methods for treating metastatic colorectal cancer comprising identifying subjects who will respond favorably to anti-VEGF therapy. According to certain aspects of the invention, subjects are identified based on their expression level of VEGF-A. Favorable response to anti-VEGF therapy is indicated by elevated expression levels of VEGF-A. Also disclosed herein is the use of VEGF-A as a marker for identifying metastatic colorectal cancer- bearing subjects who are expected to have better relative survival outcomes to an anti-VEGF therapy.
